1027930-49-9

Upstream product

• 1826-67-1 vinyl magnesium bromide 
• 169203-64-9 1-(4-bromo-2-fluorobenzyl)-4-ethyl-5-formyl-2-propyl-1H-imidazole 
• 76283-09-5 4-bromo-2-fluorobenzyl bromide 
• 51436-99-8 2-fluoro-4-bromotoluene 

Downstream Products

• 1026502-55-5 N-{3-[5-Ethyl-3-(3-fluoro-2'-sulfamoyl-biphenyl-4-ylmethyl)-2-propyl-3H-imidazol-4-yl]-3-oxo-propyl}-N-pyridin-3-yl-butyramide 
• 169203-69-4 1-(4-bromo-2-fluorobenzyl)-5-<3-(N-pyridin-3-ylbutanamido)propanoyl>-4-ethyl-2-propyl-1H-imidazole 
• 1026402-33-4 1-[3-(4-Bromo-2-fluoro-benzyl)-5-ethyl-2-propyl-3H-imidazol-4-yl]-3-(pyridin-3-ylamino)-propan-1-one 
• 169203-68-3 1-(4-bromo-2-fluorobenzyl)-4-ethyl-5-propenoyl-2-propyl-1H-imidazole 

Relevant academic research and scientific papers

Balanced AT1/AT2 receptor antagonists. 4. XR510 and related 5-(3- amidopropanoyl)imidazoles possessing equal affinity for the AT1 and AT2 receptors

The identification of the AT1 and AT2 receptor subtypes has stimulated interest in developing balanced angiotensin II receptor antagonists. A series of 5-(3-amidopropanoyl)imidazoles has been prepared which possess balanced affinity for the AT1 and AT2 receptors. XR510 (1), 1-[[2'- [[(isopentoxycarbonyl)amino]sulfonyl]-3-fluoro(1,1'-biphenyl)-4-yl]methyl]- 5-[3-(N-pyridin-3-ylbutanamido)propanoyl]-4-ethyl-2-propyl-1H-imidazole, potassium salt, exhibits subnanomolar affinity for both receptor sites. XR510 is very active in lowering blood pressure in renal hypertensive rats and furosemide-treated dogs following oral administration.